Skip to main content
Caplight Logo









Tr1X

Tr1X

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://tr1x.bio/

Last Round

Grant

Jun 25, 2026

Total Funding Raised

$78M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Tr1X is a biotechnology company developing off-the-shelf allogeneic regulatory T cell therapies to treat autoimmune and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyregulatory T cellTreg therapyallogeneic cell therapyoff-the-shelf therapyCAR-Tr1autoimmune diseaseGraft-versus-Host DiseaseGvHDmultiple sclerosisimmune toleranceclinical-stage biotechbiotech startupIND applicationdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tr1X Comparables

Compare Tr1X with similar companies based on industry and business-model similarity.

Tr1X comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GentiBio
87%
Cellenkos, Inc.
86%
Sonoma Biotherapeutics
84%

Tr1X Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 25, 2026
Series BOct 14, 2025
GrantApr 4, 2025
GrantJan 1, 2024

Key People

Founding team and executive leadership

David de Vries

CEO

Executive Team

Tr1X Investors

Notable investors and investment history

Tr1X investors
InvestorRounds
The Column GroupSeries B, Grant
Neva SGRGrant, Series B
The Chernin GroupGrant
California Institute for Regenerative MedicineGrant
Alexandria Venture InvestmentsGrant, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 35% MoM.

  • Jun 25, 2026

    Received $8M grant from California Institute for Regenerative Medicine.

Tr1X Filings

Explore SEC and related filing metadata, where available.

Tr1X filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tr1X's valuation, stock price, and market status.

Is Tr1X a public or private company?

Tr1X is a private company.

What is the current stock price of Tr1X?

Tr1X is a private company with no public stock price. No recent secondary market data is available.

How much is Tr1X worth (valuation)?

Valuation information for Tr1X is not publicly available.

Can I buy Tr1X stock?

Tr1X shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Tr1X's last funding round?

Tr1X's most recent funding round was VC Round on October 14, 2025.

Who are the main investors in Tr1X?

Key investors in Tr1X include The Column Group, The Chernin Group.

Will Tr1X IPO soon?

No public IPO plans have been announced for Tr1X.

How can I track Tr1X secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tr1X's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range38
Year Founded2018
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?